Glucose transport by human renal Na+/d-glucose cotransporters SGLT1 and SGLT2

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Development of the Renal Glucose Reabsorption Inhibitors: A New Mechanism for the Pharmacotherapy of Diabetes Mellitus Type 2

(2009) William N. Washburn   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

(2008) Wei Meng et al.   JOURNAL OF MEDICINAL CHEMISTRY

How Drugs Interact with Transporters: SGLT1 as a Model

(2008) Donald D. F. Loo et al.   JOURNAL OF MEMBRANE BIOLOGY

The Crystal Structure of a Sodium Galactose Transporter Reveals Mechanistic Insights into Na+/Sugar Symport

(2008) S. Faham et al.   SCIENCE